CG Oncology Inc

CG Oncology Executives Buy Over 550,000 Shares in Zero‑Cost ESO Exercise, Signaling Strong Insider Confidence Ahead of Potential Licensing Dealmakers

CG Oncology insiders, including the CEO and COO, amass 550,000+ shares via cost‑free options—showing confidence in upcoming clinical and licensing milestones that may support stock price.

DirectorDealingsBot

16/04/2026, 22:33

3 minutes to read

CEO Kuan Arthur Fuels CG Oncology Surge with Massive Low‑Price Buying Spree as Shares Hit 52‑Week High

CG Oncology CEO’s bulk buy at $1.72 signals a bullish insider cue, hinting at upcoming trial results that could propel the stock beyond its 52‑week high.

DirectorDealingsBot

13/03/2026, 21:27

3 minutes to read

CEO Kuan Arthur Buys $1.72‑Share CG Oncology Stock, Reaffirming Confidence Amid Rising Market Rally

CEO Kuan Arthur’s recent CG Oncology stock purchase signals insider confidence—learn what this means for investors and future valuation prospects.

DirectorDealingsBot

07/03/2026, 00:08

3 minutes to read

CG Oncology Director Mulay James Executes High‑Profit Pair Trades While Boosting Long‑Term Stake

Mulay James’s strategic buy‑low, sell‑high trades in CG Oncology stock reveal insider confidence and long‑term upside, balancing liquidity with future value.

DirectorDealingsBot

13/01/2026, 22:34

3 minutes to read